Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Dual-action bacterial cancer therapy shrinks aggressive breast tumors in mouse models

Tumors that resist immune attack, recur and spread pose a major challenge to cancer treatment. Because certain bacteria naturally accumulate within tumors, they serve as potential carriers for anticancer agents. Addressing this, a research team from the Republic of Korea—led by professor John Hwa Lee from the Laboratory of Veterinary Public Health, College of Veterinary Medicine, Jeonbuk National…

Dual-action bacterial cancer therapy shrinks aggressive breast tumors in mouse models

Researchers in South Korea have engineered a strain of Salmonella Typhimurium bacterial therapy that effectively diminishes aggressive breast tumors in mouse models. The bacteria were made safe by removing genes that make them harmful, making them reliant on a nutrient called tryptophan which they can only obtain from the tumor environment.

This engineered strain, named JOL3136, was designed to produce two cancer-fighting substances. Firstly, a protein called apoptin that triggers cancer cell death, and secondly, an immune system stimulant known as a CEA epitope protein. The research team found that mice treated with JOL3136 experienced a significant reduction in tumor size, with results being more than double the reduction seen in mice treated with a bacterial vector alone.

This bacterium also seemed to activate the immune system, enhancing the body's ability to fight the cancer. However, the study did not specify how much of the positive effects were due to the apoptin, the CEA epitope, or both working together. Furthermore, while promising, these findings must be confirmed in human studies, and the safety of this bacterial delivery system needs to be thoroughly evaluated before it can be considered for clinical use.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Monday 16 November →